Literature DB >> 27295566

A novel evaluation of optimality for randomized controlled trials.

Jo Wick1, Scott M Berry1,2, Hung-Wen Yeh1,3, Won Choi3,4, Christina M Pacheco3,5, Christine Daley3,4,5, Byron J Gajewski1,3,5,6.   

Abstract

Balanced two-arm designs are more powerful than unbalanced designs and, consequently, Bayesian adaptive designs (BADs) are less powerful. However, when considering other subject- or community-focused design characteristics, fixed two-arm designs can be suboptimal. We use a novel approach to identify the best two-arm study design, taking into consideration both the statistical perspective and the community's perception. Data envelopment analysis (DEA) was used to estimate the relative performance of competing designs in the presence of multiple optimality criteria. The two-arm fixed design has enough deficiencies in subject- and community-specific benefit to make it the least favorable study design.

Entities:  

Keywords:  Accrual; American Indians; community based participatory research; longitudinal

Mesh:

Year:  2016        PMID: 27295566      PMCID: PMC5154788          DOI: 10.1080/10543406.2016.1198367

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  20 in total

1.  Adaptive clinical trials: the promise and the caution.

Authors:  Donald A Berry
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

2.  Predicting accrual in clinical trials with Bayesian posterior predictive distributions.

Authors:  Byron J Gajewski; Stephen D Simon; Susan E Carlson
Journal:  Stat Med       Date:  2008-06-15       Impact factor: 2.373

3.  Moving forward: breaking the cycle of mistrust between American Indians and researchers.

Authors:  Christina M Pacheco; Sean M Daley; Travis Brown; Melissa Filippi; K Allen Greiner; Christine M Daley
Journal:  Am J Public Health       Date:  2013-10-17       Impact factor: 9.308

4.  Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.

Authors:  Byron J Gajewski; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen Dimachkie; Laura Herbelin; Richard Barohn
Journal:  Stat Med       Date:  2015-01-07       Impact factor: 2.373

Review 5.  Bayesian clinical trials in action.

Authors:  J Jack Lee; Caleb T Chu
Journal:  Stat Med       Date:  2012-06-18       Impact factor: 2.373

6.  Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors.

Authors:  Yu Jiang; Steve Simon; Matthew S Mayo; Byron J Gajewski
Journal:  Stat Med       Date:  2014-11-06       Impact factor: 2.373

7.  All Nations Breath of Life: using community-based participatory research to address health disparities in cigarette smoking among American Indians.

Authors:  Christine Makosky Daley; K Allen Greiner; Niaman Nazir; Sean M Daley; Cheree L Solomon; Stacy L Braiuca; T Edward Smith; Won S Choi
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

8.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Authors:  Chunyan Cai; Suyu Liu; Ying Yuan
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

9.  Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs.

Authors:  Mi-Ok Kim; Chunyan Liu; Feifang Hu; J Jack Lee
Journal:  Stat Med       Date:  2014-05-29       Impact factor: 2.373

10.  Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives.

Authors:  David K Espey; Xiao-Cheng Wu; Judith Swan; Charles Wiggins; Melissa A Jim; Elizabeth Ward; Phyllis A Wingo; Holly L Howe; Lynn A G Ries; Barry A Miller; Ahmedin Jemal; Faruque Ahmed; Nathaniel Cobb; Judith S Kaur; Brenda K Edwards
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

View more
  1 in total

1.  Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials.

Authors:  Byron J Gajewski; Jeffrey Statland; Richard Barohn
Journal:  Stat Biopharm Res       Date:  2019-06-26       Impact factor: 1.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.